Env 2-3
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV InfectionsHIV Seronegativity
Phase 1
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
CompletedNCT00000779
End: 1996-09-30Target: 130Updated: 2021-11-04
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
CompletedNCT00000632
End: 1992-05-31Updated: 2021-11-02
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
CompletedNCT00000746
End: 1994-07-31Target: 56Updated: 2021-11-04
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
CompletedNCT00000972
End: 1992-04-30Updated: 2021-11-04
A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
CompletedNCT00000958
End: 1995-09-30Target: 8Updated: 2021-11-04